StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$676.21−13.44 (-1.95%)

Close on Nov 20, 2026Market cap $53.27BP/E 47.6Yield –

IDEXX Laboratories revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

IDEXX Laboratories's revenue for the twelve months ending Jun 30, 2026 was $4.55B, up 12.8% year over year. For fiscal 2025 it was $4.30B, up 10.4% from the year before. Over ten years it grew 10.4% a year on average. The highest annual figure on record is $4.30B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.30B+10.4%
FY2024Dec 31, 2024$3.90B+6.5%
FY2023Dec 31, 2023$3.66B+8.7%
FY2022Dec 31, 2022$3.37B+4.7%
FY2021Dec 31, 2021$3.22B+18.8%
FY2020Dec 31, 2020$2.71B+12.5%
FY2019Dec 31, 2019$2.41B+8.8%
FY2018Dec 31, 2018$2.21B+12.4%
FY2017Dec 31, 2017$1.97B+10.9%
FY2016Dec 31, 2016$1.78B+10.8%
FY2015Dec 31, 2015$1.60B+7.8%
FY2014Dec 31, 2014$1.49B+7.9%
FY2013Dec 31, 2013$1.38B+6.5%
FY2012Dec 31, 2012$1.29B+6.1%
FY2011Dec 31, 2011$1.22B+10.4%
FY2010Dec 31, 2010$1.10B+7.0%
FY2009Dec 31, 2009$1.03B+0.7%
FY2008Dec 31, 2008$1.02B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.22B+9.7%
Q1 FY2026Mar 31, 2026$1.14B+14.3%
Q4 FY2025Dec 31, 2025$1.09B+14.3%
Q3 FY2025Sep 30, 2025$1.11B+13.3%
Q2 FY2025Jun 30, 2025$1.11B+10.6%
Q1 FY2025Mar 31, 2025$998.43M+3.6%
Q4 FY2024Dec 31, 2024$954.29M+5.8%
Q3 FY2024Sep 30, 2024$975.54M+6.6%
Q2 FY2024Jun 30, 2024$1.00B+6.4%
Q1 FY2024Mar 31, 2024$964.10M+7.1%
Q4 FY2023Dec 31, 2023$901.60M+8.8%
Q3 FY2023Sep 30, 2023$915.53M+8.8%
Q2 FY2023Jun 30, 2023$943.63M+9.7%
Q1 FY2023Mar 31, 2023$900.20M+7.6%
Q4 FY2022Dec 31, 2022$828.57M+3.4%
Q3 FY2022Sep 30, 2022$841.66M+3.9%
Q2 FY2022Jun 30, 2022$860.55M+4.2%
Q1 FY2022Mar 31, 2022$836.55M+7.6%
Q4 FY2021Dec 31, 2021$801.09M+11.1%
Q3 FY2021Sep 30, 2021$810.42M+12.3%
Q2 FY2021Jun 30, 2021$826.14M+29.6%
Q1 FY2021Mar 31, 2021$777.71M+24.2%
Q4 FY2020Dec 31, 2020$720.94M+19.1%
Q3 FY2020Sep 30, 2020$721.79M+19.2%
Q2 FY2020Jun 30, 2020$637.59M+2.8%
Q1 FY2020Mar 31, 2020$626.34M+8.7%
Q4 FY2019Dec 31, 2019$605.45M+10.2%
Q3 FY2019Sep 30, 2019$605.30M+11.0%
Q2 FY2019Jun 30, 2019$620.10M+6.8%
Q1 FY2019Mar 31, 2019$576.06M+7.1%
Q4 FY2018Dec 31, 2018$549.39M+8.5%
Q3 FY2018Sep 30, 2018$545.45M+10.9%
Q2 FY2018Jun 30, 2018$580.75M+14.1%
Q1 FY2018Mar 31, 2018$537.66M+16.4%
Q4 FY2017Dec 31, 2017$506.12M+14.2%
Q3 FY2017Sep 30, 2017$491.98M+9.7%
Q2 FY2017Jun 30, 2017$508.94M–
Q1 FY2017Mar 31, 2017$462.02M–
Q4 FY2016Dec 31, 2016$443.00M–
Q3 FY2016Sep 30, 2016$448.31M–

More IDEXX Laboratories figures

See a number that looks wrong?